Drug Trial Radar · NCT03341962
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
263
Actual
Start
Mar 15, 2018
Primary completion
Nov 16, 2022
Study completion Nov 16, 2022
Sponsor
- Lead sponsor
- Immunic AGIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment extension in moderate-to-severe ulcerative colitis (CALDOSE-1).
Conditions
- Ulcerative Colitis
Interventions
IMU-838Drug
IMU-838 tablet
PlaceboDrug
Tablets manufactured to mimic IMU-838 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Induction Phase: Symptomatic Remission and Endoscopic Healing at Week 10Time frame: 10 weeks
Locations
131 sites in 19 countries. Site status is shown where the registry gives one.
Del Sol Research Management, LLC
Tucson, Arizona
Axis Clinical Trials
Los Angeles, California
Ventura Clinical Trials
Ventura, California
Alliance Medical Research, LLC
Lighthouse PT, Florida
Medley Research Associates
Medley, Florida
Global Life Research LLC
Miami, Florida
Family Clinical Trials
Pembroke Pines, Florida
Clinical Research Trials of Florida, Inc.
Tampa, Florida
Atlanta Gastroenterology Associates, LLC
Atlanta, Georgia
McFarland Clinic, P.C.
Ames, Iowa
Commonwealth Clinical Studies
Brockton, Massachusetts
PMG Research of Salisbury, LLC
Salisbury, North Carolina
Clinical Trials of South Carolina
Charleston, South Carolina
First Street Surgical Hospital
Bellaire, Texas
Digestive Health Specialists
Tacoma, Washington
Durres Regional Hospital
Durrës, Albania
Regional Hospital of Shkoder
Shkoder, Albania
University Hospital Center Mother Teresa
Tirana, Albania
Gomel Regional Clinical Hospital
Homyel, Belarus
Republican Scientific and Practical Center for Radiation Medicine and Human Ecology
Homyel, Belarus
Vitiebsk State Order of Peoples' Friendship Medical University
Vitebsk, Belarus
University Clinical Centre of the Republic of Srpska, Internal Medicine Clinic, Department of Gastroenterology and Hepatology
Banja Luka, Bosnia and Herzegovina
University Clinical Hospital Mostar, Internal Medicine Clinic, Department of Gastroenterology
Mostar, Bosnia and Herzegovina
Multiprofile Hospital for Active Treatment Blagoevgrad AD
Blagoevgrad, Bulgaria
Mhat Byala
Byala, Bulgaria
Multiprofile Hospital for Active Treatment "Dr. Hristo Stambolski" EOOD
Kazanlak, Bulgaria
Medical Center "Medconsult Pleven" OOD
Pleven, Bulgaria
Medical Center Exacta Medica
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD, Plovdiv, Gastroenterology clinic
Plovdiv, Bulgaria
Medical Center "Hera" EOOD
Sofia, Bulgaria
Diagnostic-Consulting Center "Convex" EOOD
Sofia, Bulgaria
General Hospital Bjelovar
Bjelovar, Croatia
Clinical Hospital Center Osijek
Osijek, Croatia
Clinical Hospital Center Rijeka
Rijeka, Croatia
Clinical Hospital Center Split
Split, Croatia
General Hospital Vukovar
Vukovar, Croatia
Clinical Hospital Center Zagreb
Zagreb, Croatia
Clinical Hospital Dubrava
Zagreb, Croatia
Polyclinic Solmed Zagreb
Zagreb, Croatia
Clinical Hospital Center Split
Zagreb, Croatia
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.